Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2020 | Future of imaging and theranostics in prostate cancer

Jeremie Calais • 9 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer

Jeremie Calais, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA, discusses the future of radioactive imaging and theranostics in the diagnosis and treatment of prostate cancer and highlights the possibility of novel targets for imaging and treatment in addition to PSMA. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Jeremie Calais

Advances in next-generation PSMA-targeted radioligand therapy
2:09
Advances in next-generation PSMA-targeted radioligand therapy
Jeremie Calais • 1 Jun 2026
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
2:22
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
Jeremie Calais • 1 Jun 2026
AcTION: Phase I trial of 225Ac-PSMA-617 radioligand therapy in mCRPC
1:13
AcTION: Phase I trial of 225Ac-PSMA-617 radioligand therapy in mCRPC
Jeremie Calais • 1 Jun 2026
CONVERGE-01 part 3: rosopatamab tetraxetan in Lu-PSMA-pretreated mCRPC
1:21
CONVERGE-01 part 3: rosopatamab tetraxetan in Lu-PSMA-pretreated mCRPC
Jeremie Calais • 1 Jun 2026

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals